MoonLake Immunotherapeutics (NASDAQ:MLTX) Downgraded by Zacks Research to “Strong Sell”

MoonLake Immunotherapeutics (NASDAQ:MLTX) was downgraded by research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued on Tuesday,Zacks.com reports.

Other equities research analysts also recently issued reports about the company. Wolfe Research downgraded MoonLake Immunotherapeutics from an “outperform” rating to an “underperform” rating in a research report on Tuesday, September 30th. Oppenheimer restated an “outperform” rating and set a $30.00 price target on shares of MoonLake Immunotherapeutics in a report on Thursday, November 6th. BTIG Research raised shares of MoonLake Immunotherapeutics from a “neutral” rating to a “buy” rating and set a $24.00 price objective for the company in a research note on Friday, January 9th. Jefferies Financial Group cut shares of MoonLake Immunotherapeutics from a “buy” rating to a “hold” rating and set a $8.00 price objective on the stock. in a research report on Monday, September 29th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of MoonLake Immunotherapeutics in a report on Wednesday, October 8th. Seven research analysts have rated the stock with a Buy rating, five have given a Hold rating and five have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $25.77.

MoonLake Immunotherapeutics Trading Up 2.3%

Shares of MLTX opened at $16.71 on Tuesday. The stock has a market capitalization of $1.07 billion, a PE ratio of -5.03 and a beta of 1.21. The company’s fifty day moving average is $14.15 and its 200 day moving average is $29.78. The company has a debt-to-equity ratio of 0.25, a quick ratio of 8.50 and a current ratio of 8.50. MoonLake Immunotherapeutics has a fifty-two week low of $5.95 and a fifty-two week high of $62.75.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last posted its earnings results on Wednesday, November 5th. The company reported ($1.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.21). During the same period in the previous year, the company posted ($0.56) EPS. Sell-side analysts expect that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current fiscal year.

Insider Buying and Selling at MoonLake Immunotherapeutics

In other MoonLake Immunotherapeutics news, insider Kristian Reich sold 130,000 shares of the firm’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $15.08, for a total transaction of $1,960,400.00. Following the transaction, the insider owned 72,908 shares of the company’s stock, valued at approximately $1,099,452.64. This trade represents a 64.07% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Da Silva Jorge Santos sold 130,000 shares of MoonLake Immunotherapeutics stock in a transaction on Monday, December 8th. The shares were sold at an average price of $15.08, for a total value of $1,960,400.00. Following the completion of the transaction, the chief executive officer owned 2,948,577 shares in the company, valued at $44,464,541.16. This represents a 4.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 402,908 shares of company stock worth $5,987,162 over the last 90 days. 12.02% of the stock is currently owned by company insiders.

Institutional Trading of MoonLake Immunotherapeutics

Large investors have recently bought and sold shares of the stock. FNY Investment Advisers LLC acquired a new stake in shares of MoonLake Immunotherapeutics during the third quarter worth $28,000. Bank of America Corp DE raised its stake in shares of MoonLake Immunotherapeutics by 64.7% in the third quarter. Bank of America Corp DE now owns 4,532 shares of the company’s stock worth $32,000 after purchasing an additional 1,781 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in MoonLake Immunotherapeutics by 115.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,919 shares of the company’s stock valued at $42,000 after buying an additional 3,166 shares during the last quarter. Covestor Ltd acquired a new position in MoonLake Immunotherapeutics in the 3rd quarter worth approximately $46,000. Finally, BNP Paribas Financial Markets raised its position in MoonLake Immunotherapeutics by 18.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 7,296 shares of the company’s stock worth $52,000 after buying an additional 1,158 shares during the last quarter. Hedge funds and other institutional investors own 93.85% of the company’s stock.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunomodulatory therapies for autoimmune and inflammatory diseases. The company leverages a proprietary platform designed to selectively modulate key immune cell populations, aiming to restore immune balance and reduce tissue damage with targeted biologic candidates.

Its lead asset, MLTX101, is a recombinant immune cell modulator in clinical development for myositis, including inclusion body myositis and dermatomyositis.